| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | 0.0073 | 0.9 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.9 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |